Grants paid by Kaleidoscope of Hope Foundation Inc
EIN 22-3744037 · Madison, NJ · Form 990, Schedule I · NTEE H123
Kaleidoscope of Hope Foundation Inc of Madison, NJ (EIN 22-3744037) reported 22 grants paid totaling $692,000 to 16 recipients in tax years 2019–2024, on Form 990, Schedule I. Derived from IRS e-file data, dataset version 2026.09.0, built 2026-09-03.
Grants paid
$692,000
22 grants
Recipients
16
distinct organizations
Tax years
2019–2024
6 filings in the corpus
By tax year
| Tax year | Grants paid | Amount paid | Approved for future |
|---|---|---|---|
| 2019 | 6 | $172,000 | — |
| 2020 | 2 | $100,000 | — |
| 2021 | 4 | $95,000 | — |
| 2022 | 3 | $100,000 | — |
| 2023 | 4 | $150,000 | — |
| 2024 | 3 | $75,000 | — |
Top recipients
The 16 recipients receiving the most from Kaleidoscope of Hope Foundation Inc, by grants paid, out of 16 distinct recipients.
| Recipient | Match | Location | Grants | Total paid | Latest year |
|---|---|---|---|---|---|
| Trustees of the Univeristy of Pennsylvania 23-1352685 | A | Philadelphia, PA | 5 | $175,000 | 2024 |
| Memorial Sloan Kettering Cancer Center 91-2154267 | A | New York, NY | 1 | $50,000 | 2019 |
| Thomas Jefferson University 23-1352651 | A | Philadelphia, PA | 1 | $50,000 | 2020 |
| Women & Infant Hospital of Rhode Island 05-0258937 | A | Providence, RI | 1 | $50,000 | 2022 |
| University of Texas Md Anderson Cancer Center 74-6001118 | A | Houston, TX | 2 | $50,000 | 2023 |
| Whitehead Institue for Biomedical Research 06-1043412 | A | Cambridge, MA | 1 | $50,000 | 2021 |
| Temple University - of the Commonwealth System of Higher Education 23-1365971 | A | New York, NY | 1 | $50,000 | 2023 |
| Memorial Sloan Kettering Cancer Center 13-1924236 | A | New York, NY | 1 | $50,000 | 2020 |
| Stevens Institute of Technology 22-1487354 | A | Hoboken, NJ | 1 | $25,000 | 2023 |
| University of Maryland Baltimore 31-1678679 | A | Baltimore, MD | 1 | $25,000 | 2019 |
| The Ohio State University Comprehensive Cancer Center 31-1301428 | A | Columbus, OH | 1 | $25,000 | 2019 |
| Ohio University 31-6402269 | A | Athens, OH | 1 | $25,000 | 2024 |
| Corporating Mercer University 58-0566167 | A | Macon, GA | 1 | $25,000 | 2024 |
| Monell Chemical Senses Center 23-2020897 | A | Philadelphia, PA | 2 | $22,000 | 2021 |
| Penn Vet Working Dog Center Univ of Pennsylvania | U | Philadelphia, PA | 1 | $10,000 | 2019 |
| Institute for Cancer Reseach DBA Fox Chase Cancer Center 23-6296135 | A | Philadelphia, PA | 1 | $10,000 | 2021 |
Match tier: A Reported EIN · B Exact name and place · C Strong name match · D Probable name match · U Unresolved. Tiers C and D are inferred, not reported; see how matching works.
Every grant
All 22 grant rows this organization reported, most recent first.
| Tax year | Recipient | Match | Amount | Type | Purpose | Source filing |
|---|---|---|---|---|---|---|
| 2024 | Corporating Mercer University Macon, GA | A | $25,000 | paid | TO SUPPORT OVARIAN CANCER RESEARCH | 202631889349301113 |
| 2024 | Trustees of the University of Pennsylvania Philadelphia, PA | A | $25,000 | paid | INVESTIGATION OF A NOVEL P53 STABILIZING TARGETED TREATMENT COMBINATION IN TP53 WILD TYPE OVARIAN CANCER. | 202631889349301113 |
| 2024 | Ohio University Athens, OH | A | $25,000 | paid | TO SUPPORT OVARIAN CANCER RESEARCH | 202631889349301113 |
| 2023 | Trustees of the Univeristy of Pennsylvania Philadelphia, PA | A | $50,000 | paid | INVESTIGATION OF A NOVEL P53 STABILIZING TARGETED TREATMENT COMBINATION IN TP53 WILD TYPE OVARIAN CANCER. | 202412399349301001 |
| 2023 | Temple University - of the Commonwealth System of Higher Education New York, NY | A | $50,000 | paid | UNDERSTANDING THE ROLE OF CARM 1 IN REGULATION OF CYTOKINE-MEDIATED ANTITUMOR RESPONSE IN OVARIAN CANCER. | 202412399349301001 |
| 2023 | University of Texas Md Anderson Cancer Center Houston, TX | A | $25,000 | paid | TO IDENTIFY LIQUID BIOPSY (EXTRACELLULAR VESICLES)BASED MOLECULAR PREDICTORS OF DISEASE PATTERNS FROM PATIENTS FROM MATCHED TISSUES AND BLOOD FROM PATIENTS WITH COMPLETE GROSS RESECTION AND PATIENTS WITH EXCELLENT AND POOR RESPONSE TO CHEMOTHERAPY, FOLLOWED BY CLINICAL VALLIDATION OF OUR FINDING IN PATIENTS WITH HIGHGRADE SEROUS OVARIAN CANCER. | 202412399349301001 |
| 2023 | Stevens Institute of Technology Hoboken, NJ | A | $25,000 | paid | NUTRITIONAL SUPPLEMENT TAURINE SUPPRESSES OVARIAN CANCER. | 202412399349301001 |
| 2022 | Women & Infant Hospital of Rhode Island Providence, RI | A | $50,000 | paid | DETERMINE SPATIALLY RESOLVED IMMUNE RESPONSES TO CHEMOTHERAPY IN HIGH GRADE SEROUS OVARIAN CANCER AND DETERMINE LEVELS OF SERUM LAG3, PD1, ICOS, AND OX40 THROUGHOUT THE COURSE OF CHEMOTHERAPY TREATMENT AND WHETHER THEY CORRELATE WITH PATIENT CLINICAL OUTCOMES. | 202340759349300834 |
| 2022 | University of Texas Md Anderson Cancer Center Houston, TX | A | $25,000 | paid | TO IDENTIFY LIQUID BIOPSY (EXTRACELLULAR VESICLES)BASED MOLECULAR PREDICTORS OF DISEASE PATTERNS FROM PATIENTS FROM MATCHED TISSUES AND BLOOD FROM PATIENTS WITH COMPLETE GROSS RESECTION AND PATIENTS WITH EXCELLENT AND POOR RESPONSE TO CHEMOTHERAPY, FOLLOWED BY CLINICAL VALLIDATION OF OUR FINDING IN PATIENTS WITH HIGHGRADE SEROUS OVARIAN CANCER. | 202340759349300834 |
| 2022 | Trustees of the University of Pennsylvania Philadelphia, PA | A | $25,000 | paid | CLEAR CELL OVARIAN CANCER (CCOC) IS OFTEN RESISTANT TO STANDARD OF CARE CHEMOTHERAPY AND HAS LIMITED TREATMENT OPTIONS. DR. XU IS IDENTIFYING EFFECTIVE TREATMENT OPTIONS FOR CCOC BY COMBINATION OF DNA DAMARGE INHIBITORS AND BET INHIBITOR, AND ALSO DISCOVERING NEW TARGETS BY CRISPR SCREEN. WITH THE SUPPORT FROM KOH FOUNDATION, DR. XU WILL BE ABLE TO HAVE SUPPLIES AND ANIMALS TO CONTINUE THE STUDY AND IDENTIFY EFFECTIVE THERAPEUTICS FOR CCOC. | 202340759349300834 |
| 2021 | Whitehead Institue for Biomedical Research Cambridge, MA | A | $50,000 | paid | TO SUPPORT RESEACH ON NEW STRATEGIES TO TARGET HIGH-GRADE SEROUS OVARIAN CARCINOMA. | 202241339349303884 |
| 2021 | The Trustees of the University of Pennsylvania Philadelphia, PA | A | $25,000 | paid | CLEAR CELL OVARIAN CANCER (CCOC) IS OFTEN RESISTANT TO STANDARD OF CARE CHEMOTHERAPY AND HAS LIMITED TREATMENT OPTIONS. DR XU IS IDENTIFYING EFFECTIVE TREATMENT OPTIONS FOR CCOC BY COMBINATION OF DNA DAMAGE INHIBITORS AND BET INHIBITOR, AND ALSO DISCOVERING NEW TARGETS BY CRISPR SCREEN. WITH THE SUPPORT OF KOH FOUNDATION, DR XU WILL BE ABLE TO HAVE SUPPLIES AND ANIMALS TO CONTINUE THE STUDY AND IDENTIFY EFFECTIVE THERAPUTICS FOR CCOC. | 202241339349303884 |
| 2021 | Monell Chemical Senses Center Philadelphia, PA | A | $10,000 | paid | DE-CONSTRUCTION OF THE OVARIAN CANCER ODOR SIGNATURE USING ANALYTICAL ORGANIC CHEMISTRY AND MEDICAL DETECTOR | 202241339349303884 |
| 2021 | Institute for Cancer Reseach DBA Fox Chase Cancer Center Philadelphia, PA | A | $10,000 | paid | EXAMINING BRAC1 MUTATIONS IN AN OVARIAN CANCER MOUSE MODEL | 202241339349303884 |
| 2020 | Thomas Jefferson University Philadelphia, PA | A | $50,000 | paid | NOVEL PERSONALIZED MECP2 DIRECTED EPIGENETIC THERAPY IN HIGH GRADE SEROUS OVARIAN CANCERS | 202101769349301105 |
| 2020 | Memorial Sloan Kettering Cancer Center New York, NY | A | $50,000 | paid | INTEGRATED GENETIC & METHYLATION PROFILING OF LOW GRADE. SEROUS OVARIAN CARCINOMA TO IDENTITY OF RESPONSE TO CHEMOTHERY | 202101769349301105 |
| 2019 | Stevens Institue of Technology Hoboken, NJ | A | $50,000 | paid | APPLICATION OF PHOTOREACTIVE PROBES AND FIBOR OPTIC DEVICES FOR DETECTION OF FALLOPIAN TUBE CELL TRANFORMATION IN ORGANOTYPIC MODEL OF OVARIAN CANCER | 202111769349301206 |
| 2019 | Memorial Sloan Kettering Cancer Center New York, NY | A | $50,000 | paid | IMPLANTABLE NANOSENSOR FOR EARLY STAGE DETECTION OF OVARIAN CANCER | 202111769349301206 |
| 2019 | University of Maryland Baltimore Baltimore, MD | A | $25,000 | paid | TARGETING THE PGE2 EP4 RECEPTOR AS A MECHANISM FOR IMPROVED CHEMOTHERAPEUTIC RESPONSE FOR EPITHELIAL OVARIAN CANCER | 202111769349301206 |
| 2019 | The Ohio State University Comprehensive Cancer Center Columbus, OH | A | $25,000 | paid | EXOSOME ACUTE PHASE PROTEINS (APPS) AS POTENTIAL BIOMARKERS FOR EARLY DETECTION OF OVARIAN CANCER. | 202111769349301206 |
| 2019 | Monell Chemical Senses Center Philadelphia, PA | A | $12,000 | paid | IDENTIFYING THE CONSTITUENTS IN THE OVARIAN CANCER ODOR SIGNATURE | 202111769349301206 |
| 2019 | Penn Vet Working Dog Center Univ of Pennsylvania Philadelphia, PA | U | $10,000 | paid | TO SPONSOR LUCY FOR TRAINING AS A SEARCH AND RESCUE DOG | 202111769349301206 |
Match tier: A Reported EIN · B Exact name and place · C Strong name match · D Probable name match · U Unresolved. Tiers C and D are inferred, not reported; see how matching works.
Recipient matching for this dataset version has not yet completed its independent precision check. Tier A rows carry the EIN the filer reported; tiers B–D are the matcher's inference and should be read as leads until the check is published on the methodology page.
Source filings
Every figure above is traceable to one of these IRS e-file returns by its OBJECT_ID.
| Form | Tax year | Period end | Filed | Schema | IRS OBJECT_ID |
|---|---|---|---|---|---|
| 990 | 2024 | 2024-12-31 | not stated | 2024v5.5 | 202631889349301113 |
| 990 | 2023 | 2023-12-31 | not stated | 2023v5.1 | 202412399349301001 |
| 990 | 2022 | 2022-12-31 | not stated | 2022v4.1 | 202340759349300834 |
| 990 | 2021 | 2021-12-31 | not stated | 2021v4.2 | 202241339349303884 |
| 990 | 2020 | 2020-12-31 | not stated | 2020v4.1 | 202101769349301105 |
| 990 | 2019 | 2019-12-31 | not stated | 2019v5.2 | 202111769349301206 |
Derived from IRS Form 990 e-file XML; recipient identities from the IRS Exempt Organizations Business Master File. Dataset version 2026.09.0, built 2026-09-03. The same rows as Parquet: manifest; as JSON: /api/funders/223744037.json.
The same organization elsewhere in the program: exempt status and filing health · federal awards · grant guidance · open opportunities.
This is informational only, derived from public data on the dates shown. It is not an eligibility determination, and not legal, tax, or accounting advice. Verify against the official source before relying on it.